Xcout IntelBarinthus Biotherapeutics plc. competitors & alternatives
The 12 closest competitors and alternatives to Barinthus Biotherapeutics plc. among biotech companies — ranked by similarity to what Barinthus Biotherapeutics plc. actually does, not by market-cap band.
Subscribe to see Barinthus Biotherapeutics plc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Barinthus Biotherapeutics plc.
Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical firm, is dedicated to pioneering innovative T-cell immunotherapies. These cutting-edge treatments are engineered to harness the body's own immune system to effectively combat chronic infectious diseases, autoimmune disorders, and various cancers. The company is actively progressing a robust portfolio of experimental medicines spanning diverse medical fields. Prominent among these is VTP-300, an immunotherapeutic candidate striving to achieve a functional cure for chronic Hepatitis B virus (HBV) infection. Also in development is VTP-200, a non-surgical therapeutic option aimed at persistent high-risk human papillomavirus (HPV). For autoimmune conditions, VTP-1000 is an autoimmune candidate leveraging the proprietary SNAP-TI platform to treat celiac disease. Additionally, VTP-850 is a next-generation immunotherapeutic designed to address recurrent prostate cancer. Furthermore, the preclinical candidate VTP-1100 utilizes the SNAP-CI platform in its development as a potential treatment for HPV-related cancers. Originally established in 2016 under the name Vaccitech plc, the company rebranded to Barinthus Biotherapeutics plc in November 2023. Its main office is located in Harwell, United Kingdom.
Barinthus Biotherapeutics plc. at a glance
Barinthus Biotherapeutics plc. is a biotech company headquartered in Germantown, United Kingdom, founded in 2021. It is publicly listed (BRNS) with a market capitalisation of $24.2M. Xcout tracks 17 named people at Barinthus Biotherapeutics plc., including William J. Enright (Chief Executive Officer & Director).
Barinthus Biotherapeutics plc. leadership
- William J. EnrightChief Executive Officer & Director
- Bill EnrightChief Executive Officer & Board Director
- Douglas J. SwirskyCFO & Principal Accounting Officer
- Leon HooftmanChief Medical Officer
- Dr. Geoffrey LynnCHIEF SCIENTIFIC OFFICER
- Dr. Leon HooftmanCHIEF MEDICAL OFFICER
11 more named people on record for Barinthus Biotherapeutics plc., with roles, board committees and tenure — see the full roster →
Top 12 Barinthus Biotherapeutics plc. competitors
Ranked by semantic similarity — how close each company is to Barinthus Biotherapeutics plc. by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Similar biotech company
Scancell Holdings plc is a clinical-stage biopharmaceutical firm focused on discovering and developing innovative vaccine and antibody treatments. Its mission is to address significant unmet medical needs in both cancer and infectious diseases. The company's pipeline features several promising candidates, including SCIB1, currently in Phase II clinical trials for metastatic melanoma; SCIB2, aimed at non-small cell lung cancer; and Modi-1, which is undergoing Phase I/II studies for various indications such as head and neck, triple-negative breast, ovarian, and renal cancers. Additionally, Scancell is advancing Modi-2, a therapeutic agent specifically designed to target homocitrullinated cancer antigens. Its development efforts also encompass SCOV1 and SCOV2 COVIDITY, a prophylactic DNA vaccine engineered to provide protection against the SARS-CoV-2 virus. Founded in 1997, Scancell Holdings plc is headquartered in Oxford, United Kingdom.
Similar biotech company
Indaptus Therapeutics, Inc. is a biotechnology company operating in the pre-clinical phase, dedicated to developing a range of immunotherapeutic products for the treatment of both cancer and viral infections. The firm's lead investigational compound, Decoy20, is currently progressing through Phase I clinical trials. This candidate is being evaluated for its capacity to elicit lasting therapeutic responses, either as a standalone agent or in combination with other treatments, for various conditions including lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as infections caused by the hepatitis B virus and human immunodeficiency virus. Initially incorporated in 2021 under the name Intec Parent, Inc., the company officially rebranded to Indaptus Therapeutics, Inc. in August of the same year. Its corporate headquarters are situated in New York, New York.
Similar biotech company
BioVaxys Technology Corp. (BVAXF) is a clinical-stage biotechnology company primarily engaged in the development of innovative vaccine platforms targeting both antiviral diseases and various forms of cancer. Its product pipeline features several key candidates, including two SARS-CoV-2 vaccines: BVX-0320, a monovalent version, and BVX-0121, a multivalent option. In the oncology space, BioVaxys is advancing BVX-0918A, a haptenized tumor cell vaccine designed for ovarian cancer, and BVX-0918C, aimed at cervical cancer. The company also has programs addressing Human Papillomavirus (HPV), such as Papilocare for HPV-dependent cervical lesions and the BVX-0204 HPV viral vaccine. Furthermore, BioVaxys offers CoviDTH, an immunodiagnostic tool developed to detect immune system responses in individuals previously exposed to SARS-CoV-2. To support its development initiatives, BioVaxys has established several strategic collaborations. It holds a bioproduction agreement with WuXi Biologics Limited for the manufacturing of SARS-CoV-2 s-proteins, crucial components for BVX-0320 and CoviDTH. The company also has a research collaboration for BVX-0320 with The Ohio State University, Wexner School of Medicine. Additionally, Bioanalytical Systems, Inc. is conducting preclinical toxicology studies for BioVaxys' CoviDTH immunodiagnostic under a separate agreement. The company's operations are headquartered in Vancouver, Canada.
Similar biotech company
Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for obesity and various liver diseases. Its primary investigational drug, pemvidutide (proposed INN, previously known as ALT-801), operates as a GLP-1/glucagon dual receptor agonist. This compound is currently undergoing Phase 1b clinical trials, exploring its efficacy in treating both obesity and non-alcoholic steatohepatitis (NASH). Additionally, Altimmune is advancing HepTcell, an immunotherapeutic candidate, through Phase 2 clinical trials. This therapy is designed for individuals suffering from chronic hepatitis B virus infection. The enterprise, initially named Vaxin Inc., officially adopted the Altimmune, Inc. moniker in September 2015. Established in 1997, the company maintains its corporate headquarters in Gaithersburg, Maryland.
Similar biotech company
SkinBioTherapeutics Plc is a life sciences enterprise dedicated to enhancing human health through the exploration and development of technologies that harness the power of the human microbiome. The company has developed two primary technological platforms: SkinBiotix: This innovative solution is designed to strengthen the skin's natural barrier, offer protection against infections, and promote the repair of damaged skin. AxisBiotix: Focusing on the intricate link between gut health and skin conditions, this technology aims to mitigate the symptoms experienced by individuals with psoriasis. SkinBioTherapeutics serves a wide range of industries, including cosmetic and pharmaceutical skincare, nutritional supplements, and infection control. The company maintains active collaborations with key partners: Croda Plc; the University of Manchester, for the creation of microbiome formulations that bolster the immune system; and Winclove Probiotics B.V., with whom it's developing a unique probiotic blend derived from specific bacterial species known to influence psoriasis pathways. Originally founded in 2015 as Skinbiotix Ltd, the company adopted its current name, SkinBioTherapeutics plc, in December 2016. Its operations are headquartered in Newcastle upon Tyne, United Kingdom.
Biotechnology
Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for inflammatory and autoimmune diseases. Headquartered in California, the company advances a robust clinical pipeline and operates as a publicly traded enterprise.
Biotechnology
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients’ HBV-specific immune response by inhibiting PD-L1. The company has licensing agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize products with LNP delivery technology. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation was incorporated in 2005 is headquartered in Warminster, Pennsylvania.
Similar biotech company
Oxford Biomedica plc is a biopharmaceutical firm focused on the discovery, advancement, and sophisticated bioprocessing of innovative cell and gene therapies. Operating globally, with a strong presence across Europe, the company organizes its activities into two segments: Platform and Product. Its proprietary LentiVector platform technology facilitates the integration of genes into non-dividing cells, such as neurological cells in the brain and retinal cells in the eye, and can incorporate diverse therapeutic genes. The company's developmental pipeline includes promising candidates like Axo-Lenti-PD, a gene-based treatment for Parkinson's disease. Other pre-clinical stage programs feature OXB-302, targeting haematological tumors, and OXB-401, OXB-40X, and OXB-40Y, all addressing liver indications. Oxford Biomedica maintains numerous strategic alliances with prominent pharmaceutical entities such as Novartis, Bristol Myers Squibb, Sio Gene Therapies, Orchard Therapeutics, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium, Immatics, Arcellx, and the Vaccines Manufacturing and Innovation Centre. Additionally, it engages in research collaborations, including a partnership with Circularis Biotechnologies to identify novel tissue-specific promoters for in vivo lentiviral gene therapy, Virica Biotech for scaling viral medicines, Isolere Bio for enhancing downstream manufacturing efficiencies of biologics, and BiologIC Technologies for utilizing a novel biocomputer system in viral vector development. Founded in 1995, Oxford Biomedica plc is headquartered in Oxford, United Kingdom.
Similar biotech company
Vaccinex, Inc. is a biotechnology firm operating in the clinical stage, dedicated to identifying and developing specialized biological therapies. Its core mission is to address serious medical conditions and diseases that currently lack adequate treatment options. The company's therapeutic endeavors encompass a broad spectrum of illnesses, including various forms of cancer, neurodegenerative disorders, and autoimmune diseases. At the forefront of its pipeline is pepinemab, a humanized monoclonal antibody. This leading candidate has either concluded or is scheduled for Phase 1b/2 clinical investigations, exploring its efficacy against non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), Huntington's disease, Alzheimer's disease, osteosarcoma, and melanoma. Furthermore, Vaccinex is progressing with VX5, a human antibody targeting CXCL13, which is presently in preclinical assessment for potential application in multiple sclerosis (MS) and other autoimmune conditions. The company was established in 2001 and has its principal operations located in Rochester, New York.
Similar biotech company
Zenas BioPharma, Inc. functions as a clinical-stage biopharmaceutical firm, concentrating on the creation and market introduction of innovative, immunology-based treatments. The company's primary investigational therapy is obexelimab, a distinctive bifunctional monoclonal antibody intended to address multiple diseases such as immunoglobulin G4-related disease, multiple sclerosis, systemic lupus erythematosus, and warm autoimmune hemolytic anemia. Its developmental portfolio also features ZB002, an anti-TNFa monoclonal antibody; ZB004, a cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin fusion; ZB001, an anti-insulin-like growth factor-1 receptor monoclonal antibody; and ZB005, an anti-active complement component 1s monoclonal antibody. Established in 2019, the entity was formerly recognized as Zenas BioPharma (Cayman) Limited before adopting its current name, Zenas BioPharma, Inc., in August 2023. Its headquarters are located in Waltham, Massachusetts.
Biotechnology
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
Similar biotech company
BrightPath Biotherapeutics Co., Ltd. specializes in the development of innovative cancer immunotherapies. Among its leading candidates is GRN-1201, currently undergoing Phase II clinical studies for non-small cell lung cancer and Phase I studies for melanoma. The company's diverse development portfolio further encompasses BP1101, a neoantigen vaccine; BP1209, a platform for personalized neoantigen cancer vaccines; and BP1401, an agonist for toll-like receptor 9. Other therapeutic avenues include an induced pluripotent stem cell (iPSC)-derived regenerated NKT cell therapy aimed at head and neck cancer, and BP2301, an autologous HER2 chimeric antigen receptor-T (CAR-T) cell therapy targeting solid tumor sarcomas. Beyond its clinical-stage assets, BrightPath Biotherapeutics is also engaged in early-stage discovery efforts for new antibodies, including BP1200, which targets CD73; BP1210, an immune checkpoint inhibitor; and additional antibody candidates such as BP1202, BP1206, and BP1211. Established in Tokyo, Japan, in 2003, the company operated as GreenPeptide Co., Ltd. until its rebranding to BrightPath Biotherapeutics Co., Ltd. in July 2017.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Barinthus Biotherapeutics plc. and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Barinthus Biotherapeutics plc.and every competitor above — in one live dashboard.
Subscribe to Xcout Intel →